The Netherlands: Drug Substance Manufacturing Lonza, Moderna Further Collaborate for Covid-19 Vaccine Moderna
Lonza has expanded its collaboration with Moderna for drug substance manufacturing of the Covid-19 Vaccine Moderna. A new drug substance manufacturing line will also be installed at Lonza’s Geleen site in the Netherlands.
Basel/Switzerland – Lonza has recently announced the expansion of its collaboration with Moderna. The expanded collaboration will further extend the manufacture of the drug substance for the Covid-19 Vaccine Moderna and provides for the installation of a new manufacturing line for drug substance production at Lonza’s Geleen site in the Netherlands.
The new production line in Geleen will complement Lonza’s existing drug substance production network for Covid-19 Vaccine Moderna and deliver a crucial manufacturing step to increase overall drug substance output. As such, the new production line will contribute to the supply of up to an additional 300 million doses per year, at a 50ug dose, once operating at full capacity.
The new production line in Geleen, the Netherlands is expected to be operational by the end of 2021.
In May 2020, Lonza and Moderna announced a ten-year strategic collaboration agreement to enable the manufacture of Moderna’s Covid-19 vaccine and additional Moderna products in the future. Since then, Lonza has installed three production lines at its Visp (CH) site and one production line in Portsmouth, USA. In April 2021, Lonza and Moderna entered a new agreement to add three further production lines at its Visp (CH) site.
Lonza will leverage its existing infrastructure in Geleen, the Netherlands to provide fast build-out and ramp-up of operations.